Evidence map›Paper›PMID 41157578›Full record

ArticleViruses2025

Preclinical Evaluation of the Efficacy of α-Difluoromethylornithine and Sulindac Against SARS-CoV-2 Infection.

Natalia A Ignatenko, Hien T Trinh, April M Wagner, Eugene W Gerner, Christian Bime, Chiu-Hsieh Hsu, David G Besselsen

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Natalia A IgnatenkoDepartment of Cellular and Molecular Medicine, The University of Arizona, Tucson, AZ 85724, USA.ORCID 0000-0002-8096-1340
Hien T TrinhValley Fever Center for Excellence, The University of Arizona, Tucson, AZ 85724, USA.ORCID 0000-0002-7744-799X
April M WagnerUniversity Animal Care, The University of Arizona, Tucson, AZ 85724, USA.ORCID 0000-0002-1570-8103
Eugene W GernerDepartment of Cellular and Molecular Medicine, The University of Arizona, Tucson, AZ 85724, USA.
Christian BimeDepartment of Medicine, College of Medicine-Phoenix, The University of Arizona, Phoenix, AZ 85004, USA.
Chiu-Hsieh HsuMel and Enid Zuckerman College of Public Health, The University of Arizona, Tucson, AZ 85724, USA.
David G BesselsenUniversity Animal Care, The University of Arizona, Tucson, AZ 85724, USA.ORCID 0000-0001-5890-0501

Funding

Targeting polyamines to suppress SARS-CoV-2 related diseaseUG3TR003597 · NCATS · UNIVERSITY OF ARIZONA · PI BESSELSEN, DAVID G, IGNATENKO, NATALIA A · 2021 to 2022
$614k
Targeting polyamines to suppress SARS-CoV-2 related diseaseUH3TR003597 · NCATS · UNIVERSITY OF ARIZONA · PI BIME, CHRISTIAN, IGNATENKO, NATALIA A · 2023 to 2023
$153k
NCATS NIH HHS UG3 TR003597NCATS NIH HHS UG3TR003597NCATS NIH HHS UH3 TR003597
6 · The paper itself

Abstract

Despite numerous research efforts and several effective vaccines and therapies developed against coronavirus disease 2019 (COVID-19), drug repurposing remains an attractive alternative approach for treatment of SARS-CoV-2 variants and other viral infections that may emerge in the future. Cellular polyamines support viral propagation and tumor growth. Here we tested the antiviral activity of two polyamine metabolism-targeting drugs, an irreversible inhibitor of polyamine biosynthesis, α-difluoromethylornithine (DFMO), and a non-steroidal anti-inflammatory drug (NSAID), Sulindac, which have been previously evaluated for colon cancer chemoprevention. The drugs were tested as single agents and in combination in the human Calu-3 lung adenocarcinoma and Caco-2 colon adenocarcinoma cell lines and the

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentEflornithineSulindacAnimalsCaco-2 CellsCell Line, TumorCOVID-19Disease Models, AnimalDrug Evaluation, PreclinicalFemaleHumansMiceMice, TransgenicSARS-CoV-2Antiviral AgentsEflornithineSulindacantiviral drugsCOVID-19 mouse modelDFMOpolyaminesSARS-CoV-2Sulindac

Identifiers

PMID41157578
PMCPMC12567796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.